Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Adaptive Biotechnologies Corporation
The allowed claims cover compositions and methods that allow for Next Generation Sequencing (NGS) to be applied to cells of the adaptive immune system
SEATTLE, Oct. 17, 2013 /PRNewswire/ -- Adaptive Biotechnologies Corporation, a pioneer in the field of genomic immune profiling, announced today that the Company has obtained a Notice of Allowance in U.S. Patent Application Serial No. 12/794,507, titled "Method of Measuring Adaptive Immunity," exclusively licensed by Adaptive Biotechnologies from the Fred Hutchinson Cancer Research Center.
The complexity of the adaptive immune system, marked by millions of unique genetic receptors on the surface of immune fighter cells (T-cells and B-cells), is what enables the body to defend against a vast array of potential pathogens. A critical first step in profiling the adaptive immune system is the generation of millions of replicas of the DNA of these receptors to prepare them for high-throughput sequencing. Strands of nucleic acid called primers are required for successful DNA replication, or amplification. In order to account for all of the possible receptors of the immune system, the Company first pioneered immune profiling by combining these primers together into one reaction, referred to as a multiplex polymerase chain reaction (PCR).
The allowed claims for this foundational case broadly cover compositions and methods for Adaptive's revolutionary immunoSEQTM assay technology, which use these multiplex PCR primers in a single reaction to provide high-resolution analysis of a subject's adaptive immune system. This powerful, enabling technology is increasingly being used for diverse clinical applications to monitor a wide variety of immune-mediated diseases, including cancer, autoimmune disorders, transplant response and infectious diseases. This broad patent positions Adaptive as a significant intellectual property stakeholder for next generation adaptive immune system analysis technologies.
"We are thrilled to have received this allowance from the USPTO," remarked CEO and co-founder, Chad Robins. "Adaptive is a pioneer in the immunosequencing field and we are amassing an intellectual property portfolio that builds off of this foundational case to support our pipeline of assays that offer researchers and clinicians a reliable, quantitative method to characterize the adaptive immune system." Robins further explained that the company has already launched its clonoSEQTM assay for monitoring Minimal Residual Disease ("MRD") in blood-based cancers and anticipates the launch of other assay into the clinic in the near future to support the diagnosis and staging of cancer patients.
About Adaptive Biotechnologies
Adaptive Biotechnologies Corporation ("Adaptive" or the "Company") is a pioneer in immunosequencing diagnostics, with a focus in oncology. The Company leverages advances in next generation sequencing ("NGS") to profile T-Cell and B-Cell Receptors ("TCRs" and "BCRs"). This breakthrough enables in-depth characterization of the immune system, which is the primary defense against cancer. By incorporating immunosequencing into clinical care, Adaptive can enhance the diagnosis, prognosis, and monitoring of cancer patients. The Company's first clinical application, clonoSEQTM, is for monitoring Minimal Residual Disease ("MRD") in blood-based cancers. The Company recently launched clonoSEQTM as a CLIA certified Laboratory Developed Test ("LDT") in the second quarter of 2013. Improving the ability to accurately detect and track residual disease at a molecular level affords clinicians the potential to detect relapse earlier and improve patient care. Adaptive is currently validating additional oncology diagnostics to quantify the presence and clonality of Tumor Infiltrating Lymphocytes ("TIL") and to create a reliable measure of "immunocompetency" to predict or monitor response to cancer treatments that directly alter the host immune system. Adaptive incubates and validates potential clinical products by offering fee-for-service access to its proprietary immune profiling sequencing technology under the brand name immunoSEQTM.
©2012 PR Newswire. All Rights Reserved.